Cerus Corporation (CERS)’s Stock Is Buy After Touching 52-Week High

May 15, 2018 - By Adrian Mccoy

Investors sentiment increased to 1.45 in Q4 2017. Its up 0.13, from 1.32 in 2017Q3. It increased, as 6 investors sold Cerus Corporation shares while 25 reduced holdings. 14 funds opened positions while 31 raised stakes. 58.96 million shares or 2.97% more from 57.26 million shares in 2017Q3 were reported.
Tiaa Cref Invest Mgmt Limited Liability Corporation invested in 0% or 335,333 shares. Millennium Management Limited Liability has invested 0% in Cerus Corporation (NASDAQ:CERS). Envestnet Asset Management reported 0% stake. Voya Inv Ltd Limited Liability Company owns 52,929 shares. 27,500 are owned by Elm Advsrs Lc. Shufro Rose Lc owns 14,000 shares or 0% of their US portfolio. Baker Bros L P stated it has 0.29% in Cerus Corporation (NASDAQ:CERS). Berson & Corrado Invest Lc invested in 0.11% or 54,675 shares. Lesa Sroufe, Washington-based fund reported 540,752 shares. Bessemer Grp Incorporated accumulated 0% or 820 shares. 539,948 are owned by Citadel Advisors Limited Liability. Ny State Common Retirement Fund, New York-based fund reported 125,149 shares. Credit Suisse Ag has invested 0% in Cerus Corporation (NASDAQ:CERS). Geode Capital Mgmt Lc, Massachusetts-based fund reported 990,324 shares. Parallax Volatility Advisers L P owns 15,708 shares for 0% of their portfolio.

Since March 10, 2018, it had 1 buy, and 5 insider sales for $597,723 activity. Greenman William Mariner sold 17,766 shares worth $87,795. Menard Chrystal sold $22,793 worth of Cerus Corporation (NASDAQ:CERS) on Saturday, March 10. Another trade for 3,680 shares valued at $18,328 was made by Benjamin Richard J on Saturday, March 10. Moore Carol sold $23,151 worth of stock or 4,686 shares. 150,011 shares valued at $773,199 were bought by CORASH LAURENCE M on Monday, March 12.

The stock of Cerus Corporation (NASDAQ:CERS) hit a new 52-week high and has $7.13 target or 9.00 % above today’s $6.54 share price. The 5 months bullish chart indicates low risk for the $853.76M company. The 1-year high was reported on May, 15 by Barchart.com. If the $7.13 price target is reached, the company will be worth $76.84 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.61% or $0.04 during the last trading session, reaching $6.54. About 175,975 shares traded. Cerus Corporation (NASDAQ:CERS) has risen 26.07% since May 15, 2017 and is uptrending. It has outperformed by 14.52% the S&P500.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on August, 2. They expect $-0.11 EPS, up 31.25 % or $0.05 from last year’s $-0.16 per share. After $-0.11 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 2 analysts covering Cerus Corp (NASDAQ:CERS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cerus Corp has $700 highest and $5.0 lowest target. $6.50’s average target is -0.61% below currents $6.54 stock price. Cerus Corp had 5 analyst reports since November 30, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, March 8 by Cantor Fitzgerald. On Monday, January 8 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock has “Buy” rating by Robert W. Baird on Thursday, November 30. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, May 8. On Wednesday, January 24 the stock rating was maintained by Robert W. Baird with “Buy”.

More news for Cerus Corporation (NASDAQ:CERS) were recently published by: Globenewswire.com, which released: “New Research Coverage Highlights Cerus, Health Insurance Innovations, Tetra Tech, Ferro, Dril-Quip, and MSC …” on May 15, 2018. Seekingalpha.com‘s article titled: “Cerus’ (CERS) CEO Obi Greenman on Q1 2018 Results – Earnings Call Transcript” and published on May 08, 2018 is yet another important article.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $853.76 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

WP Twitter Auto Publish Powered By : XYZScripts.com